IPOs
Nov 14, 2017
Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires
Novartis ventures itself into developing new editing technology Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&D work in the arena of cell and gene therapy. The deal involves Novartis using the gene editing technology ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
